Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Neurology ; 73(10): 781-9, 2009 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-19738173

RESUMEN

BACKGROUND: Human T-lymphotropic virus (HTLV) type I is the causative agent of HTLV-associated myelopathy (HAM)/tropical spastic paraparesis, and a number of HAM cases with HTLV-II infection have also been reported. However, despite some reports, it is unclear whether HTLV-I or -II infection is associated with other neurologic manifestations. METHODS: An analysis of medical histories and screening neurologic examinations from a prospective cohort of 153 HTLV-I, 388 HTLV-II, and 810 HTLV-seronegative individuals followed up for means of 11.5, 12.0, and 12.2 years was performed. Participants diagnosed with HAM were excluded. We calculated odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for age, sex, race or ethnicity, income, educational attainment, body mass index, alcohol and cigarette consumption, injection drug use, diabetes, and hepatitis C virus status, using generalized estimating equations for repeated measures. RESULTS: HTLV-I and -II participants were more likely than seronegative participants to have leg weakness (ORs 1.67 [95% CI 1.28-2.18] and 1.44 [1.16-1.78]), impaired tandem gait (ORs 1.25 [95% CI 1.07-1.47] and 1.45 [1.27-1.64]), Babinski sign (ORs 1.54 [95% CI 1.13-2.08] and 1.51 [1.18-1.93]), impaired vibration sense (ORs 1.16 [95% CI 1.01-1.33] and 1.27 [1.14-1.42]), and urinary incontinence (ORs 1.45 [95% CI 1.23-1.72] and 1.70 [1.50-1.93]). For both HTLV-I and -II participants, higher odds of sensory neuropathy by monofilament examination were no longer significant after adjustment for confounding. CONCLUSIONS: These results provide strong evidence that human T-lymphotropic virus (HTLV)-I and -II are associated with a spectrum of predominantly motor abnormalities in patients without overt HTLV-associated myelopathy. Further investigation of the clinical course and etiology of these abnormalities is warranted.


Asunto(s)
Infecciones por HTLV-I/epidemiología , Infecciones por HTLV-II/epidemiología , Virus Linfotrópico T Tipo 1 Humano , Virus Linfotrópico T Tipo 2 Humano , Trastornos de la Destreza Motora , Enfermedades del Sistema Nervioso , Paraparesia Espástica Tropical , Adolescente , Adulto , Anciano , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Infecciones por HTLV-I/diagnóstico , Infecciones por HTLV-II/diagnóstico , Virus Linfotrópico T Tipo 1 Humano/aislamiento & purificación , Virus Linfotrópico T Tipo 2 Humano/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Trastornos de la Destreza Motora/diagnóstico , Trastornos de la Destreza Motora/epidemiología , Trastornos de la Destreza Motora/virología , Enfermedades del Sistema Nervioso/diagnóstico , Enfermedades del Sistema Nervioso/epidemiología , Enfermedades del Sistema Nervioso/virología , Paraparesia Espástica Tropical/diagnóstico , Paraparesia Espástica Tropical/epidemiología , Estudios Prospectivos , Adulto Joven
2.
J Infect Dis ; 179(5): 1055-61, 1999 May.
Artículo en Inglés | MEDLINE | ID: mdl-10191204

RESUMEN

Serologic, biochemical, and molecular analyses were used to study hepatitis G virus (HGV), antibody to the HGV envelope protein (anti-E2), risk factors, clinical significance, and the impact of HGV on coexistent hepatitis C virus (HCV). Among 329 donors with confirmed HCV infection, 12% were HGV RNA-positive and 44% were anti-E2-positive (total exposure, 56%). HGV RNA and anti-E2 were mutually exclusive except in 9 donors (1.5%); 8 of 9 subsequently lost HGV RNA but anti-E2 persisted. HGV had little impact on alanine aminotransferase, aspartate aminotransferase, or gamma-glutamyl transpeptidase in donors with HGV infection alone or those coinfected with HCV. A multivariate analysis showed that intravenous drug abuse was the leading risk factor for HGV transmission, followed by blood transfusion, snorting cocaine, imprisonment, and a history of sexually transmitted diseases. In summary, HGV and HCV infections were frequently associated and shared common parenteral risk factors; HGV did not appear to cause hepatitis or to worsen the course of coexistent hepatitis C.


Asunto(s)
Flaviviridae/aislamiento & purificación , Anticuerpos Antihepatitis/sangre , Hepatitis C/complicaciones , Hepatitis Viral Humana/complicaciones , Hepatitis Viral Humana/transmisión , ARN Viral/sangre , Adulto , Donantes de Sangre , Digoxigenina , Femenino , Flaviviridae/genética , Flaviviridae/inmunología , Hepacivirus/inmunología , Hepatitis C/transmisión , Hepatitis C/virología , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/virología , Humanos , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Factores de Riesgo , Proteínas del Envoltorio Viral/inmunología
3.
J Infect Dis ; 176(6): 1468-75, 1997 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9395356

RESUMEN

Disease associations of human T lymphotropic virus types I and II (HTLV-I and -II) infection were studied in 154 HTLV-I-infected, 387 HTLV-II-infected, and 799 uninfected blood donors. Adjusted odds ratios (ORs) and 99% confidence intervals (CIs) were derived from logistic regression models controlling for demographics and relevant confounders. All subjects were human immunodeficiency virus type 1-seronegative. HTLV-II was significantly associated with a history of pneumonia (OR, 2.6; 99% CI, 1.2-5.3), minor fungal infection (OR, 2.9; 99% CI, 1.2-7.1), and bladder or kidney infection (OR, 1.6; 99% CI, 1.0-2.5) within the past 5 years and with a lifetime history of tuberculosis (OR, 3.9; 99% CI, 1.3-11.6) and arthritis (OR, 1.8; 99% CI, 1.2-2.9). Lymphadenopathy (> or =1 cm) was associated with both HTLV-I (OR, 6.6; 99% CI, 2.2-19.2) and HTLV-II (OR, 2.8; 99% CI, 1.1-7.1) infection, although no case of adult T cell leukemia/lymphoma was diagnosed. Urinary urgency and gait disturbance were associated with both viruses. This new finding of increased prevalence of a variety of infections in HTLV-II-positive donors suggests immunologic impairment.


Asunto(s)
Infecciones por HTLV-I/complicaciones , Infecciones por HTLV-II/complicaciones , Infecciones/complicaciones , Adolescente , Adulto , Anciano , Artritis/complicaciones , Artritis/epidemiología , Donantes de Sangre , Estudios de Cohortes , Femenino , Infecciones por HTLV-I/epidemiología , Infecciones por HTLV-II/epidemiología , Humanos , Infecciones/diagnóstico , Infecciones/epidemiología , Leucemia-Linfoma de Células T del Adulto/complicaciones , Leucemia-Linfoma de Células T del Adulto/epidemiología , Modelos Logísticos , Enfermedades Linfáticas/complicaciones , Enfermedades Linfáticas/virología , Masculino , Persona de Mediana Edad , Micosis/complicaciones , Micosis/epidemiología , Oportunidad Relativa , Neumonía/complicaciones , Neumonía/epidemiología , Prevalencia , Tuberculosis/complicaciones , Tuberculosis/epidemiología , Enfermedades Urológicas/complicaciones , Enfermedades Urológicas/epidemiología
4.
Med Law ; 16(2): 339-47, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9212625

RESUMEN

Throughout the world people who have epilepsy and seizures are prohibited from donating blood. These restrictions are based on the assumption that they are prone to adverse donor reactions, specifically, syncope and convulsions. We describe a study evaluating whether that concern is warranted. During a two year period beginning in 1987, blood donors with a history of seizures were actively recruited by the American Red Cross in the state of Maryland, USA. According to accepted standards, adverse reactions were classified as "slight", for dizziness and nausea without loss of consciousness; "moderate", denoting syncope; and "severe", indicating convulsive syncope. We reviewed a total of 329,143 satisfactory blood donations, and 613 individuals reporting a history of seizures donated blood 723 times. Among donors with seizures, 186 (25.7%) were taking antiepileptic medication, and 61 (8.4%) had one or more seizures in the preceding year. Individuals with seizures had a low incidence of adverse reactions (3.34%). Although slightly higher than the entire population (2.24%), this difference was not statistically significant. In particular, the risk of syncope with or without convulsive activity was low for people with seizures (.21%) and not significantly increased as compared to other donors (.28%). Our study supports the view that individuals with seizures or epilepsy are not at greater risk for adverse reactions after blood donation. Major restrictions on individuals with epilepsy and seizures as blood donors are not warranted.


Asunto(s)
Donantes de Sangre/legislación & jurisprudencia , Epilepsia/sangre , Defensa del Paciente/legislación & jurisprudencia , Convulsiones/sangre , Adolescente , Adulto , Anciano , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/uso terapéutico , Femenino , Humanos , Masculino , Maryland , Persona de Mediana Edad , Riesgo , Síncope/etiología
5.
Transfusion ; 35(6): 470-4, 1995 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-7770896

RESUMEN

BACKGROUND: Individuals with epilepsy or seizure disorders are restricted from donating blood because of concern that they are prone to adverse donor reactions such as syncope and convulsions. A study evaluating whether that concern is warranted is reported. STUDY DESIGN AND METHODS: During a 2-year period beginning in 1987, blood donors in Maryland with a history of seizures were actively recruited by the American Red Cross. Adverse donor reactions were classified as "slight", indicating dizziness and nausea without loss of consciousness; "moderate," denoting syncope; and "severe," indicating convulsive syncope. RESULTS: There were 329,143 satisfactory blood donations; 613 individuals reporting a history of seizures donated blood a total of 723 times. Among donors with seizures, 186 (35.7%) were taking antiepileptic medication, and 61 (8.4%) had had one or more seizures in the preceding year. Individuals with seizures had a low incidence of adverse reactions (3.34%). Although this incidence was slightly higher than that in the entire population (2.24%), the difference was not significant. In particular, the risk of syncope with or without convulsive activity was low for people with seizures (0.21%) and not significantly greater than that in other donors (0.28%). CONCLUSION: Individuals with seizures or epilepsy are not at greater risk for adverse reactions after blood donation, and major restrictions on their participation as blood donors are not warranted.


Asunto(s)
Donantes de Sangre , Epilepsia/complicaciones , Convulsiones/complicaciones , Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Síncope/etiología
6.
Clin Lab Med ; 12(3): 553-76, 1992 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-1521427

RESUMEN

This article has presented an overview of developments in the treatment of HDN. The number of cases requiring treatment that have occurred in the last decade has dropped because of the development and implementation of Rh immunoprophylaxis, although this treatment still appears to be underutilized in the United States. Failure to recognize the need for immunoprophylaxis in certain situations (including unrecognized abortion) has led to a small residual population of alloimmunized mothers who will require comprehensive treatment during subsequent pregnancies. Alloimmunization to other red cell antigens remains a small but significant problem in other women. Although great advances have been made in the monitoring of these pregnancies, amniotic fluid analysis remains a mainstay for the third-trimester evaluation of alloimmunized pregnancies. Noninvasive methods such as ultrasound evaluation and the monocyte assays may supplement, but cannot entirely replace, the need for direct assessment. The most striking advancement in the evaluation and treatment of these infants has been the ability to access the fetal circulation directly through intravenous umbilical cord sampling. This method allows for an immediate assessment of fetal anemia as well as a route for direct fetal transfusion. The method has also permitted a more complete assessment of fetal physiology. However, the method may be overutilized at the present time and has some degree of risk to the fetus, even in experienced hands. Additional methods of treatment for the alloimmunized pregnancy include plasma exchange, intravenous immunoglobulin infusion, and promethazine hydrochloride. The popularity of plasma exchange has probably decreased with the advent of more direct fetal sampling and treatment techniques, but it may be useful in the treatment of first-trimester pregnancy losses. Intravenous immunoglobulin and promethazine hydrochloride appear to be promising alternatives that require more investigation. It is apparent that efforts need to be channeled towards prevention of HDN in a health system that is highly aware of increasing costs and the benefits of preventive medicine.


Asunto(s)
Transfusión de Sangre Intrauterina , Eritroblastosis Fetal/terapia , Isoinmunización Rh , Eritroblastosis Fetal/inmunología , Eritroblastosis Fetal/fisiopatología , Femenino , Humanos , Recién Nacido , Embarazo , Isoinmunización Rh/inmunología , Isoinmunización Rh/prevención & control
8.
Crit Rev Clin Lab Sci ; 21(3): 229-53, 1984.
Artículo en Inglés | MEDLINE | ID: mdl-6439468

RESUMEN

In this article, the authors examine the nature of the Du phenomenon through a comprehensive historical review beginning with the initial description of the Du factor in the 1940s. Pertinent developments in serologic testing methods and genetic concepts are described. Evidence of the importance of the Du factor in transfusion and hemolytic disease of the newborn is also presented. Selected articles on the frequency of Du in Caucasian and Negro populations are cited. Finally, the authors review current theoretical concepts concerning the nature of the Du factor, its importance in current transfusion practice and maternal Rh immune globulin administration, and the use of microscopic Du testing as a screening procedure for fetomaternal hemorrhage.


Asunto(s)
Sistema del Grupo Sanguíneo Rh-Hr/genética , Población Negra , Transfusión Sanguínea , Europa (Continente) , Femenino , Humanos , Inmunoglobulina G , Inmunoglobulina M , Isoantígenos/análisis , Métodos , Fenotipo , Embarazo , Estados Unidos , Población Blanca
9.
Transfusion ; 23(5): 396-7, 1983.
Artículo en Inglés | MEDLINE | ID: mdl-6414129

RESUMEN

Four Rh-positive patients with severe aplastic anemia received equine anti-lymphocyte globulin. Each developed a positive direct antiglobulin test. Anti-D was identified in eluates prepared from the patients' sensitized red cells. The administered lot of anti-lymphocyte globulin was found to contain anti-D. Red cell sensitization due to passively acquired Rh antibodies can result from the administration of anti-lymphocyte globulin.


Asunto(s)
Suero Antilinfocítico/administración & dosificación , Inmunización Pasiva , Isoanticuerpos/análisis , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Adolescente , Adulto , Anemia Aplásica/terapia , Animales , Niño , Preescolar , Contaminación de Medicamentos , Caballos , Humanos , Persona de Mediana Edad
10.
Transfusion ; 23(4): 300-4, 1983.
Artículo en Inglés | MEDLINE | ID: mdl-6410550

RESUMEN

The enzyme-linked antiglobulin test was used to determine the percentage of antibody removed from sensitized red cells by five elution methods: Rubin ether, xylene, digitonin-acid, glycine, and heat. Antibodies examined in the study included anti-D, -c, -E, and -K. With two examples of anti-D, more antibody was eluted by the Rubin ether method (45.5% average) than the xylene (38%) or the digitonin acid method (35%) (p less than 0.05); the glycine (8%) and heat method (15%) were less efficient. With one example of anti-E and one example of anti-c, more antibody was eluted by the ether method. The percentage of anti-K recovery, however, was greater with the digitonin acid method (45%) than with the ether (30%). We found the enzyme-linked antiglobulin test method useful in the quantitative evaluation of elution procedures.


Asunto(s)
Anticuerpos/aislamiento & purificación , Prueba de Coombs , Técnicas para Inmunoenzimas , Digitonina , Éteres , Glicina , Calor , Humanos , Sistema del Grupo Sanguíneo de Kell , Sistema del Grupo Sanguíneo Rh-Hr , Albúmina Sérica Bovina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA